In Southeast Asia, the plant has been used for years as a substitute for opium, according to the National Center for Complementary and Integrative Health. The FDA, though, thinks differently. "Basically, what the agency is saying is that kratom behaves as an opioid and that it itself has troubling side effects," said Lyndsay Meyer, a spokeswoman f
Market Research Future published a cooked research report on "Global Digital Pathology Market Research Report- Forecast to 2022"- Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.. MicroDimensions GmbH, Mikroscan Technologies, Inc., Q2 Solutions, Omnyx, LLC, GE Healthcare, Philips Healthcare, Huron Digital Pathology Inc., ViewsI
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00 a.m. Eastern Time
Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that Dr. Gabriel Mbalaviele presented data from pre-clinical studies of Aclaris...
VANCOUVER- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European patent for AQS1301, Aequus' once-weekly transdermal patch containing aripiprazole. This is the eighth...
SAN FRANCISCO- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were present
Alpha Source, Inc., Milwaukee, announced that the company has completed the acquisition of West Jordan, Utah-based BC Technical, Inc. This deal will expand Alpha Source ultrasound and bone densitometry equipment service to now include maintenance, repair, and refurbished equipment for CT, MRI, and molecular imaging modalities.
Additionally, AMN Healthcare has again been awarded a Premier contract for existing staffing services. "We are thrilled to expand our relationship with Premier," said Dan White, President of Workforce Solutions at AMN Healthcare. AMN Healthcare is now the sole-source endorsed healthcare staffing provider, Managed Service Program, Vendor Management
ENGLEWOOD, Colo.- Ampio Pharmaceuticals, Inc. announced the beginning of an Open Label Extension study of Ampion in patients with severe osteoarthritis of the knee. The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial. This OLE study will address the regulatory requ
WESTMINSTER, Colo.- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office's issuance of a patent on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide...
On November 21, 2017, Ardelyx, Inc. provided an update on the development of its cardiorenal pipeline with a focus on tenanpanor and next-generation opportunities. Following learnings from the Company's first completed Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, the Company soug
Pune, India 11/21/2017 The World Automated Hospital Beds Market is growing at a steady pace and is expected to reach USD 2,553.4 million by 2023 from USD 1,590.1 million in 2016 at a CAGR of 5.97% during the assessment period 2017-2023.. Paramount Bed Holdings Co., Ltd.. Regional Analysis of the Global Automated Hospital Beds Market: The Euro
New Delhi, India 11/20/2017 About DelveInsight. DelveInsight is a leading Market Research and Business Consulting firm focused exclusively on life sciences. It supports companies by providing end to end comprehensive solutions to improve their performance and in making long-lasting decision for their businesses.
Four years ago, radium-223 dichloride was the first therapeutic alpha-emitting radionuclide to be approved by the Food and Drug Administration for clinical use in cancer patients. A Cornell team led by Justin Wilson, assistant professor in the Department of Chemistry and Chemical Biology in the College of Arts and Sciences, and John Babich, profess
Biocon Ltds shares jumped over 7% after the company said on Monday that its manufacturing facility in Bengaluru, which had received observations relating to lapses in quality compliance earlier this year, has been cleared by the US Food and Drug Administration. The US FDA has issued an Establishment Inspection Report in relation to the cGMP inspect
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Initiation of two additional Phase 1 b/2 studies under collaboration with Genentech, following the first study which was initiated in July 2017. All studies are explorin
-BioQ Pharma Incorporated and Sophos Biotech S.r.l., both specialty pharmaceutical companies, today announced a strategic partnership agreement under which BioQ will supply and Sophos will commercialize a proprietary treatment for post-operative pain management in Italy. Giulio Cimini, CEO of Sophos, stated, We are very pleased to join with BioQ to
ROCKVILLE, Md., Nov. 21, 2017/ PRNewswire/ Some of the world's largest biopharmaceutical products, among the highest revenue generators in the pharmaceutical industry, may face competition from so-called "biosimilars," according to a new report from healthcare market research firm Kalorama Information. These close copies of biodrugs are coming to
This report on the global blood pressure monitoring devices& accessories market analyzes the current and future scenario of the global market. Rise in private and public funding for diagnostic medical devices, rising demand for advanced blood pressure monitoring devices, and favorable regulatory scenario for new devices are boosting the growth of
The FDA has created a policy framework for cellular therapies and other regenerative medicines by releasing two draft and two final guidance documents. In the guidance, the FDA takes the RMAT status created by the 21st Century Cures Act, contextualizes it against other regulatory designations and explains how and why companies may want to apply.
PETACH TIKVA, Israel- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, Can-
Cancer Prevention Pharmaceuticals, a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29 th Annual Healthcare Conference on November 28, 7:50 -8: 10 a.m. ET at the Lotte New York Palace in New York City. In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. th
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview of the company in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 2:00pm ET at the Lotte New York Palace in New York, NY.
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of a company-sponsored, adequate and well-controlled, proof-of-concept clinical trial evaluating safety,...
-Celsion Corporation today announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound 2017 5:28. The TARDOX Study, whic